ORGANIZATION
Hodanren Criticizes Zolgensma’s High NHI Price as “Result of a Money Game”
The Japanese Medical and Dental Practitioners for the Improvement of Medical Care (Hodanren) criticized Japan’s highest NHI price received by Novartis’ spinal atrophy treatment Zolgensma (onasemnogene abeparvovec) in its statement issued on May 15, saying that it is suspected as…
To read the full story
Related Article
ORGANIZATION
- PhRMA Slams CEA Expansion, Warns It Undermines Japan Growth Strategy
November 17, 2026
- UCB Japan President Kikuchi to Take Helm of EFPIA Japan
November 13, 2026
- Japan Pharmacy Group Renews Call to Scrap Off-Year Drug Price Revisions
November 13, 2026
- JPMA to Draw Up 2027 Strategic Plan Based on Industry Vision
November 13, 2026
- JMA Renews Backing for Hanako Jimi in 2028 Upper House Race
November 11, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





